Page last updated: 2024-12-05

2,4,6-triaminopyrimidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2,4,6-Triaminopyrimidine, also known as melamine, is a white, crystalline organic compound with the formula C3H6N6. It is produced industrially by the trimerization of cyanamide. Melamine is a versatile building block in the production of various polymers, including melamine-formaldehyde resins, which find applications in laminates, adhesives, and molding compounds. Melamine is also a key component in melamine-based fire retardants, which are used in textiles, plastics, and other materials. The compound is the subject of research due to its various applications, including its potential as a precursor for new pharmaceuticals and its ability to form strong hydrogen bonds, making it suitable for use in molecular recognition and sensing. Its toxicity has been studied extensively, particularly concerning its potential for causing kidney stones in infants. '

2,4,6-triaminopyrimidine: see also 2,4,6-triaminopyridinium (cation) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

2,4,6-triaminopyrimidine : An aminopyrimidine in which a pyrimidine core carries amino substituents at positions 2, 4 and 6. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID13863
CHEMBL ID571518
CHEBI ID39857
SCHEMBL ID96485
MeSH IDM0058804

Synonyms (45)

Synonym
pyrimidine-2,4,6-triyltriamine
chebi:39857 ,
ai3-60016
pyrimidine, 2,4,6-triamino-
nsc 26493
einecs 213-720-7
(4,6-diamino-pyrimidin-2-yl)-amine
nsc-26493
2,6-pyrimidinetriamine
2,6-triaminopyrimidine
1004-38-2
nsc26493
2,4,6-triaminopyrimidine
pyrimidine-2,4,6-triamine
2,4,6-pyrimidinetriamine
inchi=1/c4h7n5/c5-2-1-3(6)9-4(7)8-2/h1h,(h6,5,6,7,8,9
2,4,6-triaminopyrimidine, 97%
3ay ,
aaat
CHEMBL571518 ,
T0834
2,4,6-triaminopyrimidin-1-ium
bdbm50303515
AKOS000120081
A800202
FT-0609835
AM20070647
EPITOPE ID:119697
SCHEMBL96485
2,4,6-triamino pyrimidine
DTXSID3061394
triamino pyrimidine
W-108962
AC-22831
mfcd00006100
CS-W013516
STL510740
D6ZP6F2ECK
Q27120379
AS-10864
SY030507
2,4,6-pyrimidinetriamine; pyrimidine, 2,4,6-triamino- (6ci,7ci,8ci); 2,4,6-triaminopyrimidine; nsc 26493; pyrimidine-2,4,6-triamine
SB57795
EN300-21548
Z203045380

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" This study examined the possibility that paracellular transport is modulated by luminal GA, resulting in an enhanced rate of absorption in the small intestine."( Gum arabic (GA) modifies paracellular water and electrolyte transport in the small intestine.
Harper, RG; Rehman, KU; Teichberg, S; Wapnir, RA; Wingertzahn, MA, 2003
)
0.32

Dosage Studied

ExcerptRelevanceReference
" The ratios of the apparent off-rate and on-rate constants (the microscopic inhibition constants) thus obtained for triamterene, triaminopyrimidine (TAP), 5,6-diCl-amiloride, 5H-amiloride and amiloride itself are found to be in the mean about sevenfold smaller than the corresponding inhibition constants obtained from macroscopic dose-response curves."( Competitive blocking of epithelial sodium channels by organic cations: the relationship between macroscopic and microscopic inhibition constants.
Li, JH; Lindemann, B, 1983
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
aminopyrimidineA member of the class of pyrimidines that is pyrimidine substituted by at least one amino group and its derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Pteridine reductase 1Leishmania majorKi27.00000.03901.57184.0000AID444877
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID444877Inhibition of Leishmania major recombinant PTR12010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
Structure-based design of pteridine reductase inhibitors targeting African sleeping sickness and the leishmaniases.
AID444878Inhibition of Trypanosoma brucei recombinant PTR12010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
Structure-based design of pteridine reductase inhibitors targeting African sleeping sickness and the leishmaniases.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (38)

TimeframeStudies, This Drug (%)All Drugs %
pre-199012 (31.58)18.7374
1990's2 (5.26)18.2507
2000's7 (18.42)29.6817
2010's15 (39.47)24.3611
2020's2 (5.26)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 28.95

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index28.95 (24.57)
Research Supply Index3.66 (2.92)
Research Growth Index4.99 (4.65)
Search Engine Demand Index31.18 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (28.95)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other38 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]